202 related articles for article (PubMed ID: 33679746)
1. Somatic Mutations and the Risk of Undifferentiated Autoinflammatory Disease in MDS: An Under-Recognized but Prognostically Important Complication.
Watad A; Kacar M; Bragazzi NL; Zhou Q; Jassam M; Taylor J; Roman E; Smith A; Jones RA; Amital H; Cargo C; McGonagle D; Savic S
Front Immunol; 2021; 12():610019. PubMed ID: 33679746
[No Abstract] [Full Text] [Related]
2. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.
Oganesyan A; Hakobyan Y; Terrier B; Georgin-Lavialle S; Mekinian A
Semin Hematol; 2021 Oct; 58(4):247-253. PubMed ID: 34802547
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.
Yan X; Wang L; Jiang L; Luo Y; Lin P; Yang W; Ren Y; Ma L; Zhou X; Mei C; Ye L; Xu G; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Med; 2021 Mar; 10(5):1759-1771. PubMed ID: 33609081
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Haase D; Stevenson KE; Neuberg D; Maciejewski JP; Nazha A; Sekeres MA; Ebert BL; Garcia-Manero G; Haferlach C; Haferlach T; Kern W; Ogawa S; Nagata Y; Yoshida K; Graubert TA; Walter MJ; List AF; Komrokji RS; Padron E; Sallman D; Papaemmanuil E; Campbell PJ; Savona MR; Seegmiller A; Adès L; Fenaux P; Shih LY; Bowen D; Groves MJ; Tauro S; Fontenay M; Kosmider O; Bar-Natan M; Steensma D; Stone R; Heuser M; Thol F; Cazzola M; Malcovati L; Karsan A; Ganster C; Hellström-Lindberg E; Boultwood J; Pellagatti A; Santini V; Quek L; Vyas P; Tüchler H; Greenberg PL; Bejar R;
Leukemia; 2019 Jul; 33(7):1747-1758. PubMed ID: 30635634
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.
Lötscher F; Seitz L; Simeunovic H; Sarbu AC; Porret NA; Feldmeyer L; Borradori L; Bonadies N; Maurer B
Front Immunol; 2021; 12():800149. PubMed ID: 35126364
[TBL] [Abstract][Full Text] [Related]
6. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
7. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
8. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
[TBL] [Abstract][Full Text] [Related]
9. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.
Kulasekararaj AG; Jiang J; Smith AE; Mohamedali AM; Mian S; Gandhi S; Gaken J; Czepulkowski B; Marsh JC; Mufti GJ
Blood; 2014 Oct; 124(17):2698-704. PubMed ID: 25139356
[TBL] [Abstract][Full Text] [Related]
11. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
12. Chromosome study of 85 patients with myelodysplastic syndrome.
Musilova J; Michalova K
Cancer Genet Cytogenet; 1988 Jul; 33(1):39-50. PubMed ID: 3164239
[TBL] [Abstract][Full Text] [Related]
13. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
14. Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML.
Janiszewska H; Bąk A; Skonieczka K; Jaśkowiec A; Kiełbiński M; Jachalska A; Czyżewska M; Jaźwiec B; Kuliszkiewicz-Janus M; Czyż J; Kuliczkowski K; Haus O
Leuk Res; 2018 Jul; 70():74-78. PubMed ID: 29902706
[TBL] [Abstract][Full Text] [Related]
15. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated complications in patients with myelodysplastic syndromes--clinical and cytogenetic features.
Billström R; Johansson H; Johansson B; Mitelman F
Eur J Haematol; 1995 Jul; 55(1):42-8. PubMed ID: 7615049
[TBL] [Abstract][Full Text] [Related]
17. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
[TBL] [Abstract][Full Text] [Related]
18. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
Singhal D; Wee LYA; Kutyna MM; Chhetri R; Geoghegan J; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Hiwase S; Edwards S; Moore S; Branford S; Kuzmanovic T; Singhal N; Gowda R; Brown AL; Arts P; To LB; Bardy PG; Lewis ID; D'Andrea RJ; Maciejewski JP; Scott HS; Hahn CN; Hiwase DK
Leukemia; 2019 Dec; 33(12):2842-2853. PubMed ID: 31089247
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
20. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]